The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Eye Cancer
Shots:
- The USPTO has issued a Notice of Allowance to the patent application covering ibudilast (MN-166) as a prevention of eye cancer, patent once issued will protect it until Jul 2042
- The allowed claims cover ibudilast’s utilization for preventing, improving or minimizing uveal melanoma. It also includes oral administration, various doses, different dosing frequencies, and different treatment periods
- Ibudilast (MN-166) is a small molecule that hindered uveal melanoma migration by suppressing exosomal cell migration through macrophage migration inhibitory factor (MIF) inhibition. It further improved CD8 T cell activity in the tumor microenvironment by decreasing immune-suppressive myeloid-derived suppressor cells (MDSCs)
Ref: MediciNova | Image: MediciNova
Related News:- MediciNova Presenting New Data from the P-II Study of MN-166 (ibudilast) at Annual Meeting of the Society for Neuro-Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
